Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years

2026. szeptember 7. frissítette: GlaxoSmithKline

A Phase 3, Non-randomized, Single-arm, Open-label Study to Assess the Immunogenicity, Safety and Reactogenicity of Combined Reduced-antigen-content Diphtheria, Tetanus and Acellular Pertussis (dTpa) Vaccine, Administered as a Booster Dose in Healthy Japanese Adolescents Aged 11 Years to <13 Years

The purpose of the study is to assess the immune response, reactogenicity and safety of a booster dose of dTpa vaccine 1 month after vaccination in healthy Japanese participants aged 11 to <13 years.

A tanulmány áttekintése

Állapot

Befejezve

Beavatkozás / kezelés

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

90

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

      • Fukuoka, Japán, 812-0871
        • GSK Investigational Site
      • Hokkaido, Japán, 004-0052
        • GSK Investigational Site
      • Hokkaido, Japán, 006-0814
        • GSK Investigational Site
      • Hokkaido, Japán, 062-0907
        • GSK Investigational Site
      • Kumamoto, Japán, 862-0924
        • GSK Investigational Site
      • Mie, Japán, 511-0865
        • GSK Investigational Site
      • Osaka, Japán, 554-0014
        • GSK Investigational Site
      • Saitama, Japán, 360-0812
        • GSK Investigational Site
      • Saitama, Japán, 337-0042
        • GSK Investigational Site
      • Shizuoka, Japán, 420-8623
        • GSK Investigational Site

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Gyermek

Egészséges önkénteseket fogad

Igen

Leírás

Inclusion Criteria:

  • Participants and/or participants' parent(s)/ Legally acceptable representative(s) [LAR(s)], who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Physical or digital informed assent obtained from the participant prior to performance of any study-specific procedure.
  • Physical or digital informed consent obtained from the parent(s)/LAR(s) of the participant prior to performance of any study-specific procedure.
  • Healthy participants as established by medical history and clinical examination at screening.
  • Male/female participant between and including 11 and <13 years of age at the time of the study intervention administration (Visit 1/Day 1).
  • Previously completed all routine childhood vaccinations to the best knowledge of the participant's parent(s)/LAR(s). Participants with documented previous diphtheria, tetanus and pertussis vaccination (primary series and first booster) as per routine vaccination in Japan prior to study enrolment.
  • Participants did not receive an additional diphtheria, tetanus with or without pertussis vaccination within 5 years prior to enrolment in the study.
  • Japanese ethnic origin.
  • Participants of non-childbearing potential may be enrolled in the clinical study.
  • Participant of childbearing potential may be enrolled in the study if the participant:
  • has practiced adequate contraception for at least 30 days prior to study intervention administration, and
  • has a negative pregnancy test within 24 hours prior to the study intervention administration, and
  • has agreed to continue adequate contraception during the entire treatment period and for 8 weeks after completion of the study intervention administration series.

Exclusion Criteria:

Medical conditions

  • History of physician-diagnosed or laboratory-confirmed diphtheria, tetanus or pertussis diseases within the past 5 years.
  • History of encephalopathy after administration of a previous dose of pertussis vaccine that could not be attributed to another identifiable cause, progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy: pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized.
  • History of transient thrombocytopenia or neurological complications following an earlier immunization against diphtheria and/or tetanus.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s) or having shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination
  • Acute or unstable chronic conditions clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
  • Condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any investigational or non-registered product other than the study intervention(s) during the period beginning 30 days before the dose of study intervention(s), or their planned use during the study period.
  • Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.
  • Chronic administration of immune-modifying drugs and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.

    • Up to 6 months prior to the study intervention administration:

For corticosteroids, this will mean prednisone equivalent ³0.5 mg/kg/day with maximum of 20 mg/day. Inhaled, intra-articular/intra-bursal and topical steroids are allowed.

  • Up to 6 months prior to study intervention administration: long-acting immune-modifying drugs including among others immunotherapy, monoclonal antibodies, antitumoral medication.

    • Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the dose and ending 30 days after the dose of study intervention(s) administration*, with the exception of inactivated influenza vaccine and SARS-CoV-2 vaccine which can be given at any time during the study conduct.

      *If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by public health authorities outside the routine immunization program, the time period described above can be reduced, provided it is used according to the local governmental recommendations and Sponsor is notified.

    • Planned administration of any prophylactic medication in the absence of any symptom and in anticipation of a reaction to the study intervention administration.

Prior/Concurrent clinical study participation

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention vaccine/drug/invasive medical device.

Other exclusion criteria

  • Pregnant or lactating participant.
  • History of /current chronic alcohol consumption and/or drug abuse, based on investigator's judgment.
  • Any study personnel or their immediate dependents, family, or household members.
  • Child in care.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Megelőzés
  • Kiosztás: Nem véletlenszerű
  • Beavatkozó modell: Egyetlen csoportos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: dTpa Group
Participants aged 11 to less than (<) 13 years receive the dTpa vaccine at Day 1.
Combined reduced antigen content diphtheria, tetanus and acellular pertussis (dTpa) vaccine administered at Day 1.

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Number of seropositive participants for anti-pertussis toxin (anti-PT), anti-filamentous hemagglutinin (FHA) and anti-pertactin (PRN) antibodies
Időkeret: 1 month after vaccination
Seropositivity is defined as antibody concentrations (anti-PT, anti-FHA and anti-PRN) are greater than or equal to the assessed assay cut-offs. The considered cut-off values are: anti-PT: 2.693 International Units per milliliter (IU/mL), anti-FHA: 2.046 IU/mL, anti-PRN: 2.187 IU/mL, as measured by Enzyme-Linked Immunosorbent assay (ELISA).
1 month after vaccination
Number of seroprotected participants for anti-diphteria and anti-tetanus antibodies
Időkeret: 1 month after vaccination
Seroprotection is defined as anti-diphtheria and anti- tetanus antibody concentrations being >=0.1 IU/mL as measured by ELISA.
1 month after vaccination

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Number of participants with booster-response to pertussis (PT, FHA and PRN) antigens
Időkeret: 1 month after vaccination
Booster response to PT, FHA and PRN antigens is defined as: for participants with pre-vaccination antibody concentration below the assay cut-off, post-vaccination antibody concentration >=4 times the assay cut-off; for participants with pre-vaccination antibody concentration between the assay cut-off and below 4 times the assay cut-off, post-vaccination antibody concentration >= 4 times the pre-vaccination antibody concentration; for participants with pre-vaccination antibody concentration >=4 times the assay cut-off, post-vaccination antibody concentration >=2 times the pre-vaccination antibody concentration.
1 month after vaccination
Antibody concentration against pertussis (PT, FHA, PRN) antigens
Időkeret: At baseline (Day 1) and 1 month after vaccination
At baseline (Day 1) and 1 month after vaccination
Antibody concentration for anti-diphtheria and anti-tetanus antibodies
Időkeret: At baseline (Day 1) and 1 month after vaccination
At baseline (Day 1) and 1 month after vaccination
Number of participants with solicited local adverse events (AEs)
Időkeret: From Day 1 (day of vaccination) to Day 7 post-vaccination
Solicited local AEs are pain, redness (erythema) and swelling at administration site.
From Day 1 (day of vaccination) to Day 7 post-vaccination
Number of participants with solicited systemic AEs
Időkeret: From Day 1 (day of vaccination) to Day 7 post-vaccination
Solicited systemic AEs are fever, headache, myalgia (muscle pain), arthralgia (joint pain), fatigue (tiredness) and gastrointestinal symptoms.
From Day 1 (day of vaccination) to Day 7 post-vaccination
Number of participants with unsolicited AEs
Időkeret: From Day 1 (day of vaccination) to Day 30 post-vaccination
An unsolicited AE is an AE that was either not included in the list of solicited AEs or could be included in the list of solicited AEs but with an onset outside the specified period of follow-up for solicited AEs. Unsolicited AEs include both serious and non-serious AEs.
From Day 1 (day of vaccination) to Day 30 post-vaccination
Number of participants with serious AEs (SAEs)
Időkeret: From Day 1 (day of vaccination) to Day 30 post-vaccination
An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes, is a suspected transmission of any infectious agent via an authorized medicinal product, or other situations as per investigator's judgment.
From Day 1 (day of vaccination) to Day 30 post-vaccination
Number of participants with AEs leading to study withdrawal
Időkeret: From Day 1 (day of vaccination) to Day 30 post-vaccination
From Day 1 (day of vaccination) to Day 30 post-vaccination

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2026. június 29.

Elsődleges befejezés (Tényleges)

2026. szeptember 4.

A tanulmány befejezése (Tényleges)

2026. szeptember 4.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. május 13.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. május 13.

Első közzététel (Tényleges)

2026. május 19.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. szeptember 9.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. szeptember 7.

Utolsó ellenőrzés

2026. szeptember 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

IPD megosztási időkeret

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

IPD-megosztási hozzáférési feltételek

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL
  • NEDV
  • ICF
  • CSR

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Nem

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel